Financials data is unavailable for this security.
View more
Year on year Enzo Biochem Inc had revenues fall -4.85% from 32.64m to 31.06m, though the company grew net income from a loss of 18.26m to a gain of 20.29m.
Gross margin | 43.66% |
---|---|
Net profit margin | -52.63% |
Operating margin | -50.73% |
Return on assets | -21.20% |
---|---|
Return on equity | -39.90% |
Return on investment | -34.50% |
More ▼
Cash flow in USDView more
In 2023, Enzo Biochem Inc increased its cash reserves by 268.86%, or 60.77m. Cash Flow from Investing totalled 98.98m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 36.98m for operations while cash used for financing totalled 1.13m.
Cash flow per share | -0.3197 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.35 |
---|---|
Tangible book value per share | 1.35 |
More ▼
Balance sheet in USDView more
Current ratio | 3.50 |
---|---|
Quick ratio | 3.16 |
Total debt/total equity | 0.056 |
---|---|
Total debt/total capital | 0.053 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -21.61%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 35.54 |